Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Utility Of The 21-gene Oncotype Dx Breast Recurrence Score® Assay In Node-negative Breast Cancer Patients - The Final Analysis Of The Polish Real-life Survey Pondx.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Utility Of The 21-gene Oncotype Dx Breast Recurrence Score® Assay In Node-negative Breast Cancer Patients - The Final Analysis Of The Polish Real-life Survey Pondx.

Related Experiment Video

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

520

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx.

Michał Jarząb1, Maria Litwiniuk2,3, Paige Innis4

  • 1Breast Cancer Centre, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.

Contemporary Oncology (Poznan, Poland)
|November 8, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Oncotype DX Breast Recurrence Score®adjuvant chemotherapybreast cancerreal life study

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

Related Experiment Videos

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

520
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

The Oncotype DX Breast Recurrence Score test significantly altered adjuvant chemotherapy decisions for early-stage breast cancer patients in Poland. This genomic test helped avoid unnecessary chemotherapy for many, improving treatment personalization.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Decision Support

Background:

  • Optimal treatment for early HR+, HER2-, lymph node-negative (N0) breast cancer (BC) remains challenging.
  • Clinicopathological features alone are often insufficient for accurate recurrence risk assessment.
  • Gene expression profiling tests offer a more precise method for evaluating adjuvant chemotherapy (CT) benefits.

Purpose of the Study:

  • To evaluate the impact of Oncotype DX Breast Recurrence Score (RS) results on physician treatment decisions for adjuvant CT.
  • To assess the real-world application of Oncotype DX Breast RS in the Polish population.
  • To determine how genomic profiling influences chemotherapy recommendations in early-stage BC.

Main Methods:

  • The PONDx survey analyzed data from 204 patients with HR+, HER2-, N0 BC across 8 Polish clinical centers.
  • Data collected included clinicopathological features and treatment changes post-Oncotype DX Breast RS testing.
  • Treatment recommendations (CT + endocrine therapy vs. ET alone) were compared before and after genomic test results were available.

    • Main Results:

    • Initial CT recommendations were 44.8%, decreasing significantly by 25.5% after RS results (p<0.05).
    • Treatment de-escalation occurred in 62.2% of patients initially recommended for CT.
    • Treatment escalation to CT occurred in 29.7% of patients initially recommended for ET alone, with notable impact in post-menopausal and lobular BC patients.

    Conclusions:

    • The Oncotype DX Breast RS test significantly influenced treatment decisions, leading to a 44.3% change in patient management.
    • Genomic testing helps avoid both overtreatment and undertreatment, optimizing adjuvant therapy selection.
    • The Oncotype DX Breast RS test enhances physician confidence and improves patient management in early-stage breast cancer.